Preemptive treatment with oral ganciclovir for pediatric renal transplantation

Clinical Nephrology

Volumn 61, Issue 4, 2004, Pages 246-252

  Melgosa Hijosa, Marta ^a   Garcia Meseguer C ^a   Pena Garcia P ^a   Alonso Melgar, A ^a   Espinosa Roman L ^a   Pena Carrion A ^a   Navarro Torres, M ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Antigenemia; Cytomegalovirus infection; Kidney transplantation; Oral ganciclovir; Pediatric study; Preemptive treatment

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN A; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY; VIRUS ANTIGEN;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; ANEMIA; ANTIGEN DETECTION; ARTICLE; BLOOD CULTURE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; EARLY DIAGNOSIS; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INFECTION CONTROL; KIDNEY DYSFUNCTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MALE; PATIENT MONITORING; PEDIATRIC SURGERY; POSTOPERATIVE PERIOD; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SYMPTOMATOLOGY; THROAT CULTURE; THROMBOCYTOPENIA; URINE CULTURE; VIRUS DETECTION; VIRUS RESISTANCE;

EID: 1842790454     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp61246     Document Type: Article

References (33)

1. Ahsan N, Holman MJ, Sonderbye L, Langhoff E, Yang HC 1998 Oral ganciclovir in the prevention of cytomegalovirus infection in postkidney transplant "CMV at risk" recipients: a controlled, comparative study of two regimens (750 mg bid and 500 mg bid). Transplant Proc 30: 1383-1385
2. Ahsan N, Holman MJ, Yang HC 1997 Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients. Clin Transplant 11: 633-639
3. Aitken C, Barret-Muir W, Raferty M, Breuer J 1999 The clinical significance of ganciclovir resistance in a renal transplant patient. Nephrol Dial Transplant 14: 1050-1053
4. Akposso K, Rondeau E, Haymann JP, Peraldi MN, Marlin C, Sraer JD 1997 Long-term prognosis of renal transplantation after preemptive treatment of cytomegalovirus infection. Transplantation 63: 974-976
5. Allowance D, Neumayer HH, Legendre CM 1999 Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 340: 1462-1466
6. Boeckh M, Zaia JA, Jung D, Skettino S, Chauncey TR, Bowden RA 1998 A study of the pharmakocinetics, antiviral activity and tolerability of oral ganciclovir for CMV prophylaxis in bone marrow transplantation. Biol Blood Marrow Transplant 4: 13-19
7. Brennan DC, Garlock KA, Singer GC, Schnitzler MA, Lippmann BJ, Buller RS, Gaudreault-Keener M, Lowell JA, Shemoy S, Howard TK, Storch GA 1997 Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation 64: 1843-1846
8. Cocohoba JM, McNicholl IR 2002 Valganciclovir: an advance in CMV therapeutics. Ann Pharmacother 36: 1075-1079
9. Drew WL, Miner RC, Busch DF 1991 Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. JID 163: 716-720
10. Filler G, Lampe D, von Bredow MA, Lappenberg-Pelzer M, Rocher S, Strehlau J, Ehrich HH 1998 Prophylactic oral ganciclovir after renal transplantation-dosing and pharmacokinetics. Pediatr Nephrol 12: 6-9
11. Frenkel LM, Capparelli EV, Dankner WM, Xu J, Smith IL, Ballow A, Culnane M, Read JS, Thompson M, Mohan KM, Shaver A, Robinson CA, Stempien MJ, Burchett SK, Melvin AJ, Borkowsky W, Petru A, Kovacs A, Yogev R, Goldsmith J, McFarland EJ, Spector SA for the Pediatric AIDS Clinical Trial Group 2000 Oral ganciclovir in children: pharmakocinetics, safety, tolerance and antiviral effiects. J Infect Dis 182: 1616-1624
12. Goodrich JM, Mori M, Cleaves CA 1991 Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 325: 1601-1608
13. Gourishankar S, Wong W, Dorval M 2001 Meta-analysis of prophylaxis of CMV disease in solid organ transplantation: is ganciclovir a superior agent to acyclovir? Transplant Proc 33: 1870-1872
14. Hibberd PL, Tolkoff-Rubin NE, Conti D 1995 Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. Ann Intern Med 123: 18-25
15. Ho M 1994 Advances in understanding cytomegalovirus infection after transplantation. Transplant Proc 26: 7-11
16. Kletzmayr J, Kruezwieser E, Watkins-Riedel T, Berlakovich G, Kovarik J, Klauser R 2000 Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients. Transplantation 70: 1174-1180
17. Künzle N, Petignat C, Francioli P, Vogel G, Seydoux C, Corpataux JM, Sahli R, Meylan P 2000 Preemptive treatment approach to cytomegalovirus (CMV) infection in solid organ transplant patients: relationship between compliance with the guidelines and prevention of CMV morbidity. Transplant Infect Dis 2: 118-126
18. Kusne S, Grossi P, Irish W, St George K, Rinaldo CH, Rakela J, Fung J 1999 Cytomegalovirus pp65 antigenemia monitoring as a guide for preemptive therapy: a cost-effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 68: 1125-1131
19. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M 2000 Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356: 645-649
20. Lo CY, Ho KN, Yuen KY 1997 Diagnosing cytomegalovirus disease in CMV-seropositive renal allograft recipients: a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay. Clin Transplant 11: 286-292
21. Lo A, Stratta RJ, Egidi MF, Kizilisik AT, Shokouh Amiri MH, Grewal HP, Trofe J, Alloway RR, Gaber AO 2001 Ganciclovir prophylaxis for cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil and prednisone. Transplant Proc 33: 1796-1798
22. Nichols WG, Boeckh M 2000 Recent advances in the therapy and prevention of CMV infections. J Clin Virol 16: 25-40
23. Niubo J, Perez JL, Martinez-Lacasa JT 1996 Association of quantitative cytomegalovirus antigenemia with symptomatic infection in solid organ transplant patients. Diagn Microbiol Infect Dis 24: 19-22
24. Noble S, Faulds D 1998 Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 56: 115-146
25. Patel R, Snydman DR, Rubin RH, Ho M, Pescovitz M, Martin M, Paya CV 1996 Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 61: 1279-1289
26. Pescovitz MA, Brook B, Filo RS 1996 Pharmacokinetics of oral ganciclovir in pediatric renal transplant recipients (abstract). Abstracts of the 15th annual meeting of the American Society of Transplant Physicians, Dallas, Texas, May 26-30, 1996. Transplantation 62: 703-953
27. Sageda S, Nordal KP, Hartmann A, Sund S, Scott H, Degre M, Foss A, Levestad T, Osnes K, Fauchald P, Rollag H 2002 The impact of cytomegalovirus infection and disease on rejection episodes in renal allografts recipients. Am J Transplant 2: 850-856
28. Schmidt GM, Horak DA, Niland JC et al 1991 A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med 324: 1005-1012
29. Smallwood GA, de Vera ME, Davis L, Martinez E, Stieber AC, Heffron TG 2001 Preemptive ganciclovir for CMV viremia in liver transplantation. Transplant Proc 33: 1814-1815
30. Snydman DR 1994 Cytomegalovirus prophylaxis strategies in high-risk transplantation. Transplant Proc 26 (Suppl 1): 20-26
31. Spector SA, Busch DF, Follanabee S, Squires K, Lalezari JP, Jacobson MA, Connor JD, Jung D, Shadman A, Mastre B, Bubles W, Drew WL, AIDS Clinical Trials Group, Cytomegalovirus Cooperative Study Group 1995 Pharmacokinetic, safety and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. J Infect Dis 171: 1431-1437
32. Tanabe K, Tokumoto T, Ishikawa N 1997 Comparative study of cytomegalovirus (CMV) antigenemia assay, polymerase chain reaction, serology and shell vial assay in the early diagnosis and monitoring of CMV infection after renal transplantation. Transplantation 64: 1721-1728
33. Turgeon N, Fishman JA, Basgoz N, Tolkoff-Rubin NE, Doran M, Cosimi AB, Rubin RH 1998 Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy. Transplantation 66: 1780-1786